uracil and mgl-3196
uracil has been researched along with mgl-3196 in 15 studies
Research
Studies (15)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 10 (66.67) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chabot-Blanchet, M; Chiang, E; Guertin, MC; Kelly, MJ; Reeves, RA; Tardif, JC; Taub, R | 1 |
| Banner, B; Conde-Knape, K; Danzi, S; Dvorozniak, M; Haynes, NE; Huang, KS; Kelly, MJ; Klein, I; Larigan, JD; Mennona, F; Pietranico-Cole, S; Qian, Y; Reynolds, CH; Scott, N; So, SS; Taub, R; Thakkar, K; Tilley, J; Vermeulen, J | 1 |
| Poupon, R | 1 |
| Alkhouri, N; Bansal, MB; Bashir, MR; Baum, S; Frias, JP; Guy, CD; Harrison, SA; Moussa, SE; Moylan, CA; Neuschwander-Tetri, BA; Taub, R; Zhou, R | 1 |
| Ratziu, V | 1 |
| Alkhouri, N | 1 |
| Bellusci, L; Chiellini, G; Columbano, A; D'Amore, VM; Gul, S; Kowalik, MA; La Pietra, V; Marinelli, L; Novellino, E; Perra, A; Rapposelli, S; Runfola, M; Sestito, S | 1 |
| Bhagani, S; Guaraldi, G; Ingiliz, P; Lemoine, M; Marzolini, C; Maurice, JB; Milic, J; Monteith, K; Morse, CG; Price, JC; Sebastiani, G; Tsochatzis, E | 1 |
| Zucchi, R | 1 |
| Bruinstroop, E; Singh, BK; Sinha, RA; Yen, PM | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
| Beigelman, LN; Blatt, LM; Chanda, S; Deval, J; Gupta, K; Jekle, A; Lin, TI; Luong, XG; McGowan, D; Misner, D; Mukherjee, S; Raboisson, P; Stevens, SK; Stoycheva, A; Symons, JA; Vandyck, K; Williams, C | 1 |
| Barbone, JM; Harrison, SA; Stepanova, M; Taub, RA; Younossi, ZM | 1 |
| Bacci, A; Caddeo, A; Columbano, A; Kowalik, MA; Perra, A; Rapposelli, S; Runfola, M; Serra, M | 1 |
| Heggen, E; Hovingh, GK; Isaac, BF; Kastelein, JJP; Klausen, IC; Langslet, G; McCarty, K; Taub, R; Zhou, R | 1 |
Reviews
2 review(s) available for uracil and mgl-3196
| Article | Year |
|---|---|
Thyroid Hormone Analogues: An Update.
Topics: Acetates; Anilides; Animals; Central Nervous System Diseases; Clinical Trials as Topic; Diiodothyronines; Drug Design; Dyslipidemias; Humans; Liver Diseases; Male; Mice; Mutation; Non-alcoholic Fatty Liver Disease; Phenols; Pyridazines; Rats; Signal Transduction; Thyroid Hormone Receptors alpha; Thyroid Hormone Receptors beta; Thyroid Hormones; Thyronines; Triiodothyronine; Uracil | 2020 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
Trials
3 trial(s) available for uracil and mgl-3196
| Article | Year |
|---|---|
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.
Topics: Adult; Body Mass Index; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Hypercholesterolemia; Liver; Male; Middle Aged; Patient Safety; Pyridazines; Thyroid Gland; Thyroid Hormone Receptors beta; Thyrotropin; Thyroxine; Time Factors; Triiodothyronine; Uracil | 2013 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation; Lipids; Liver; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormone Receptors beta; Uracil | 2019 |
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Topics: Adult; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Protons; Pyridazines; Quality of Life; Treatment Outcome; Uracil | 2022 |
Other Studies
10 other study(ies) available for uracil and mgl-3196
| Article | Year |
|---|---|
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
Topics: Animals; Bone Density; Clinical Trials as Topic; Drug Discovery; Dyslipidemias; Humans; Male; Mice; Mice, Inbred C57BL; Pyridazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thyroid Hormone Receptors beta; Uracil | 2014 |
Therapeutics Highlights from ILC 2018, the EASL annual congress.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Bezafibrate; Budesonide; CCR5 Receptor Antagonists; Congresses as Topic; Fibroblast Growth Factors; Gastrointestinal Agents; Humans; Imidazoles; Liver Diseases; Pyridazines; Sulfoxides; Uracil; Ursodeoxycholic Acid | 2018 |
Improving NASH with a little help from thyromimetics.
Topics: Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormones; Uracil | 2019 |
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).
Topics: Drug Development; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormone Receptors beta; Uracil | 2020 |
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Male; Molecular Structure; Pyridazines; Rats; Rats, Inbred F344; Structure-Activity Relationship; Thyroid Hormone Receptors beta; Uracil | 2020 |
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Topics: Anti-Retroviral Agents; Chalcones; Chenodeoxycholic Acid; Cholic Acids; Clinical Trials, Phase III as Topic; Drug Interactions; HIV Infections; Humans; Imidazoles; Non-alcoholic Fatty Liver Disease; Propionates; Pyridazines; Sulfoxides; Uracil | 2020 |
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
Topics: Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Pyridazines; Thyroid Hormones; Uracil | 2020 |
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Topics: Acetates; Angiopoietin-Like Protein 4; Animals; Cell Line, Tumor; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Hepatocytes; Humans; Iodide Peroxidase; Liver; Malate Dehydrogenase; Male; Non-alcoholic Fatty Liver Disease; Organophosphonates; Phenols; Primary Cell Culture; Pyridazines; Rats; Thyroid Hormone Receptors beta; Transcription, Genetic; Uracil | 2020 |
TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Lipid Metabolism; Male; Mice; Non-alcoholic Fatty Liver Disease; Organ Size; Prodrugs; Pyridazines; Thyroid Hormone Receptors beta; Transaminases; Triglycerides; Uracil | 2021 |
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.
Topics: Heterozygote; Humans; Hyperlipoproteinemia Type II; Pyridazines; Uracil | 2022 |